Myeloid sarcoma is associated with poor clinical outcome in pediatric patients with acute myeloid leukemia
The impact of myeloid sarcoma (MS) on clinical outcome of pediatric acute myeloid leukemia (AML) patients remains controversial. Moreover, little is known about the role of stem cell transplantation (SCT) in such patients.
Clinical data of patients with AML under 18 years of age were retrieved from the TARGET dataset. We analyzed the prevalence, clinical profile, molecular characteristics, and prognosis of MS in these patients.
Among 884 pediatric patients with AML, the frequency of MS was 12.3%. Pediatric AML with MS was associated with age under 1-year, abnormal cytogenetics, and KMT2A rearrangement. Moreover, MS was associated with a low complete remission rate, high induction death, poor 5-year EFS, and OS. KMT2A rearrangement had a negative impact on clinical outcome in AML patients with MS. In addition, SCT had no significant effect on the survival of AML patients with MS. Multivariate analysis revealed that MS was an unfavorable prognostic factor in pediatric AML in terms of EFS (Hazard ratio 1.670, P < 0.001) and OS (Hazard ratio 1.623, P = 0.004).
The presence of MS at diagnosis of pediatric AML is associated with poor clinical outcomes, particularly when associated with KMT2A rearrangements. Moreover, pediatric patients with AML and MS may not benefit from SCT.
KeywordsAcute myeloid leukemia Myeloid sarcoma Pediatric patients Clinical outcome
We would like to thank all study participants and the TARGET group for making these data publicly available.
This work was supported by the National Natural Science Foundation of China (81570140 to J.P. Fang), Guangdong Science and Technology Department (2017B030314026), Natural Science Foundation of Guangdong Province, China (2018A030313680 to L.H. Xu) and the China Scholarship Council [201806385032 to L.H. Xu].
Compliance with ethical standards
Conflict of interest
We declare that we have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Cavdar AO et al (1989) High risk subgroup of acute myelomonocytic leukemia (AMML) with orbito-ocular granulocytic sarcoma (OOGS) in Turkish children. Retrospective analysis of clinical, hematological, ultrastructural and therapeutical findings of thirty-three OOGS. Acta Haematol 81:80–85. https://doi.org/10.1159/000205531 CrossRefPubMedGoogle Scholar
- Chevallier P, Labopin M, Cornelissen J, Socie G, Rocha V, Mohty M, EBMT Ao (2011) Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Haematologica 96:1391–1394. https://doi.org/10.3324/haematol.2011.041418 CrossRefPubMedPubMedCentralGoogle Scholar
- Gamis AS et al (2014) Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 32:3021–3032. https://doi.org/10.1200/JCO.2014.55.3628 CrossRefPubMedPubMedCentralGoogle Scholar
- Ganzel C et al (2016) Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group Trials, 1980–2008. J Clin Oncol 34:3544–3553. https://doi.org/10.1200/JCO.2016.67.5892 CrossRefPubMedPubMedCentralGoogle Scholar
- Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG (2010) The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study. Pediatr Blood Cancer 55:414–420. https://doi.org/10.1002/pbc.22511 CrossRefPubMedPubMedCentralGoogle Scholar
- Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG (2012) Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 58:519–524. https://doi.org/10.1002/pbc.23201 CrossRefPubMedGoogle Scholar
- Kaur V, Swami A, Alapat D, Abdallah AO, Motwani P, Hutchins LF, Jethava Y (2018) Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology 23:17–24. https://doi.org/10.1080/10245332.2017.1333275 CrossRefPubMedGoogle Scholar
- Park KU, Lee DS, Lee HS, Kim CJ, Cho HI (2001) Granulocytic sarcoma in MLL-positive infant acute myelogenous leukemia: fluorescence in situ hybridization study of childhood acute myelogenous leukemia for detecting MLL rearrangement. Am J Pathol 159:2011–2016. https://doi.org/10.1016/S0002-9440(10)63052-0 CrossRefPubMedPubMedCentralGoogle Scholar